DDrare: Database of Drug Development for Rare Diseases

218. アルポート症候群
［臨床試験数：16，薬物数：24（DrugBank：11），標的遺伝子数：5，標的パスウェイ数：27］

Searched query = "Alport syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ACE I, ATA II and Statins; ACE-inhibitor; AT1-inhibitor; Atrasentan; BARDOXOLONE METHYL; Bardoxolone; Bardoxolone Methyl; Bardoxolone methyl; Benazepril; Benazepril, Valsartan and Fluvastatin; Delix; Fluvastatin; Gold; HMG-Coenzyme inhibitor (statin); Hydroxychloroquine; Lademirsen (SAR339375); Paricalcitol; RAMIPRIL; RG-012; RG012; RTA 402; Ramipril; Spironolactone; Valsartan

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03373786 (ClinicalTrials.gov)	December 22, 2017	22/10/2017	A Study of RG-012 in Subjects With Alport Syndrome	A Phase 1, Open-Label Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of RG-012 for Injection, Including Its Effect on Renal microRNA-21, in Subjects With Alport Syndrome	Alport Syndrome	Drug: RG012	Genzyme, a Sanofi Company	NULL	Completed	18 Years	65 Years	All	4	Phase 1	United States
2	EUCTR2016-002181-32-GB (EUCTR)	07/12/2016	08/09/2016	A research study to evaluate the safety and effectiveness of RG-012 as a treatment for patients with Alport syndrome	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, Dose Selection, and Preliminary Efficacy of Weekly RG 012 Injections in Patients with Alport Syndrome - A Phase 2 Study to Evaluate Weekly RG012 Injections in Alport Syndrome	Alport syndrome is an inherited form of kidney disease caused by mutations in genes coding for the capillary basement membrane collagen IV;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]		Regulus Therapeutics Inc.	NULL	Not Recruiting			Female: yes Male: yes	30	Phase 2	France;United States;Canada;Spain;Australia;Germany;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03373786
(ClinicalTrials.gov)

December 22, 2017

22/10/2017

A Study of RG-012 in Subjects With Alport Syndrome

A Phase 1, Open-Label Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of RG-012 for Injection, Including Its Effect on Renal microRNA-21, in Subjects With Alport Syndrome

Alport Syndrome

Drug: RG012

Genzyme, a Sanofi Company

NULL

Completed

18 Years

65 Years

All

Phase 1

United States

EUCTR2016-002181-32-GB
(EUCTR)

07/12/2016

08/09/2016

A research study to evaluate the safety and effectiveness of RG-012 as a treatment for patients with Alport syndrome

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, Dose Selection, and Preliminary Efficacy of Weekly RG 012 Injections in Patients with Alport Syndrome - A Phase 2 Study to Evaluate Weekly RG012 Injections in Alport Syndrome

Alport syndrome is an inherited form of kidney disease caused by mutations in genes coding for the capillary basement membrane collagen IV;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]

Regulus Therapeutics Inc.

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

France;United States;Canada;Spain;Australia;Germany;United Kingdom